UTHR Q4 2017 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$465M+13.6% YoY

Gross Profit

$412M88.6% margin

Operating Income

$139M29.9% margin

Net Income

$19M4.1% margin

EPS (Diluted)

$0.43

QoQ Revenue Growth

+4.3%

Cash Flow

Operating Cash Flow

-$86M

Free Cash Flow

-$114M

Stock-Based Comp.

$119M

Balance Sheet

Total Assets

$2.9B

Total Liabilities

$778M

Stockholders' Equity

$2.1B

Cash & Equivalents

$705M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$465M	$409M	+13.6%
Gross Profit	$412M	$381M	+8.2%
Operating Income	$139M	$174M	-20.2%
Net Income	$19M	$110M	-82.8%

Revenue Segments

Remodulin

$180M52%

Adcirca

$93M27%

Orenitram

$48M14%

Unituxin

$25M7%